CADD and FATHMM: Comprehensive assessment of computational algorithms in predicting cancer driver mutations reverses the order
- Low severity
- Not yet reviewed
- Ordering reversal
- Different tasks across studies
Comprehensive assessment of computational algorithms in predicting cancer driver mutations ranks FATHMM above CADD in 10 of 10 comparisons; other studies rank CADD above FATHMM in 11 of 13.
An automatic lead, not a finding of error. The results below are shown as published, everywhere on the site, until a reviewer decides otherwise.
Which studies agree
3 papers rank CADD above FATHMM in 11 of their 13 comparisons and FATHMM higher in 2. Comprehensive assessment… ranks FATHMM above CADD in all 10 of its comparisons.
- Rank CADD higher (2): Livesey and Marsh 2025, ProteinGym AMFR assay-level Spearman…
- Rank FATHMM higher (1): Comprehensive assessment… (disagrees)
- Mixed (1): Clinical likelihood ratios and balanced…
Each paper sits where at least two thirds of its comparisons point; Mixed means neither model reaches two thirds. The larger, outlined dot is the paper that disagrees.
| Paper | Role | Ranks CADD higher | Ranks FATHMM higher | Ties |
|---|---|---|---|---|
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations and 4 more records · DOI | Disagrees | 0 | 10 | 0 |
| Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and 1 more record · DOI | Agrees | 7 | 0 | 0 |
| Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes and 1 more record · DOI | Agrees | 3 | 2 | 0 |
| ProteinGym AMFR assay-level Spearman comparison and 4 more records · Repository | Agrees | 1 | 0 | 0 |
Comparisons in Comprehensive assessment… (10)
Comparisons in Livesey and Marsh 2025 (7)
| Protocol | Dataset | Metric | CADD | FATHMM | Higher |
|---|---|---|---|---|---|
| Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense | Livesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each), percent | 52.1 | 22.6 | CADD |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets), percent | 40.3 | 14.6 | CADD |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets), percent | 2.89 | 2.33 | CADD |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only), percent | 39 | 12.7 | CADD |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only), percent | 41.2 | 16.1 | CADD |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only), percent | 40.3 | 14.3 | CADD |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score), percent | 42 | 15.3 | CADD |
Comparisons in Clinical likelihood ratios and balanced… (5)
Comparisons in ProteinGym AMFR assay-level Spearman… (1)
| Protocol | Dataset | Metric | CADD | FATHMM | Higher |
|---|---|---|---|---|---|
| ProteinGym clinical substitutions, supervised predictors, average AUC (commit 144fe22) | ProteinGym clinical substitution benchmark at commit 144fe22 | AUROC (ProteinGym clinical substitutions, supervised clinical predictors, Average_AUC over proteins), unitless | 0.905 | 0.723 | CADD |
What disagrees
- Other studies
- rank CADD above FATHMM in 11 of 13 comparisons
- This study
- ranks FATHMM above CADD in 10 of 10 comparisons
- Compared
- CADD, FATHMM
- Study that disagrees
- Comprehensive assessment of computational algorithms in predicting cancer driver mutations, Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB), Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability), Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability), Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)
- Other studies
9 studies
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes, Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx), ProteinGym AMFR assay-level Spearman comparison, Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML), Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8), ProteinGym clinical supervised substitutions AUC summary at commit 144fe22, ProteinGym clinical zero-shot indels AUC summary at commit 144fe22, ProteinGym clinical zero-shot substitutions AUC summary at commit 144fe22, ProteinGym zero-shot DMS substitutions Spearman summary at commit 144fe22- Rule
- Ordering reversal; different tasks across studies
- Model identity
- Matched across studies partly through links not yet reviewed
The compared numbers
Each value links to its result record and source. Compare values within one protocol; the rule compares rankings, not raw values across protocols.
Follow-up
Current state: Not yet reviewed.
No one has reviewed this finding yet.
How to help resolve this
If you know why these studies disagree, for example a different population, metric or preprocessing step, or you have a corrected value, tell us through the contribution form. A reviewer checks every submission against its source before anything changes, and the step is added to the follow-up above.
Finding discrepancy-ffd640c979fa0e23 · All contested results · How findings are made and followed up